NCT00001240

Brief Summary

This study is used by the Digestive Diseases Branch to evaluate patients with suspected abnormalities in the secretion of gastric acid. The level of gastric acid is measured by analyzing the gastric juices of each individual patient. The gastric acid sample is obtained by a procedure known as nasogastric suctioning, where a thin plastic tube is passed from the nose to the stomach. Depending on the patient's present condition further diagnostic testing may be required to achieve a diagnosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Jan 1989

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 1989

Completed
10.8 years until next milestone

First Submitted

Initial submission to the registry

November 3, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 1999

Completed
4.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2004

Completed
Last Updated

March 5, 2008

Status Verified

January 1, 2004

First QC Date

November 3, 1999

Last Update Submit

March 4, 2008

Conditions

AchlorhydriaGastrinomaZollinger Ellison Syndrome

Keywords

StomachHypersecretionHyposecretionGastrinomaZollinger-Ellison Syndrome

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Eligibility criteria not identified in the protocol.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • McArthur KE, Collen MJ, Maton PN, Cherner JA, Howard JM, Ciarleglio CA, Cornelius MJ, Jensen RT, Gardner JD. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):939-44. doi: 10.1016/s0016-5085(85)80011-1.

    PMID: 3972233BACKGROUND

  • Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT. Famotidine, a new, potent, long-acting histamine H2-receptor antagonist: comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology. 1985 Apr;88(4):1026-33. doi: 10.1016/s0016-5085(85)80024-x.

    PMID: 2857672BACKGROUND

  • Vinayek R, Howard JM, Maton PN, Wank SA, Slaff JI, Gardner JD, Jensen RT. Famotidine in the therapy of gastric hypersecretory states. Am J Med. 1986 Oct 24;81(4B):49-59. doi: 10.1016/0002-9343(86)90600-5.

    PMID: 2877575BACKGROUND

MeSH Terms

Conditions

AchlorhydriaGastrinomaZollinger-Ellison Syndrome

Condition Hierarchy (Ancestors)

Stomach DiseasesGastrointestinal DiseasesDigestive System DiseasesAcid-Base ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesCarcinoma, Islet CellAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsPancreatic NeoplasmsDigestive System NeoplasmsNeoplasms by SiteEndocrine Gland NeoplasmsPancreatic DiseasesEndocrine System DiseasesParaneoplastic Endocrine SyndromesParaneoplastic SyndromesGastrointestinal NeoplasmsPeptic UlcerDuodenal DiseasesIntestinal Diseases

Study Design

Study Type
observational
Sponsor Type
NIH

Study Record Dates

First Submitted

November 3, 1999

First Posted

November 4, 1999

Study Start

January 1, 1989

Study Completion

January 1, 2004

Last Updated

March 5, 2008

Record last verified: 2004-01

Locations

US(1)